Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292


SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

UK Health Watchdog Backs Lung Cancer Drug From Roche

05/09/2012 | 07:16pm US/Eastern

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043;

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
Recommend :
React to this article
Latest news on ASTRAZENECA PLC
11m ago AstraZeneca steps up push into cancer immunotherapy
53m ago ASTRAZENECA : *s&p capital iq raises astrazeneca price target to 4500 pence - 'h..
1h ago ASTRAZENECA : agrees strategic transaction with Almirall in respiratory disease;..
2h ago AstraZeneca raises forecasts after seeing off Pfizer
4h ago ASTRAZENECA : upgrades sales and profit forecasts
6h ago ASTRAZENECA : Raises Revenue And Earnings Guidance Despite Profit Fall
7h ago ASTRAZENECA : second quarter and half year results 2014
7h ago ASTRAZENECA : Second Quarter & Half Year Results 2014
7h ago ASTRAZENECA : Pipeline
7h ago ASTRA AND PFIZER : it's a conscious uncoupling
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Income Statement Evolution
AstraZeneca plc : Income Statement Evolution
More Financials
Dynamic quotes